The present invention relates to pharmaceutical compositions comprising 4-pregenen-11-17-21-triol-3,20-dionederivatives, and their use as pharmaceuticals as modulators of theglucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). Theinventionrelates specifically to the use of these compounds and their pharmaceuticalcompositions totreat ocular conditions associated with the glucocorticoid receptors (GR)and/or themineralocorticoid receptors (MR).
